Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ashok Gupta

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
British Journal of Clinical Pharmacology|April 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjectsShringi Sharma, Xavier Pepin, Jean Cheung, et al.
Archives of Pathology & Laboratory Medicine|November 21, 2018
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial CarcinomaMagdalena Zajac, Anne-Marie Boothman, Yong Ben, et al.
Chemical Research in Toxicology|February 3, 2012
Cytochrome P450 11A1 bioactivation of a kinase inhibitor in rats: use of radioprofiling, modulation of metabolism, and adrenocortical cell lines to evaluate adrenal toxicityDonglu Zhang, Oliver Flint, Lifei Wang, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignanciesLaura Q M Chow, Derek I Jonker, Grace K Dy, et al.
Clinical Lung Cancer|July 23, 2019
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer PatientsSriram Sridhar, Luis Paz-Ares, Hao Liu, et al.
Cancer Immunology Research|January 14, 2014
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitorMargaret K Callahan, Gregg Masters, Christine A Pratilas, et al.
Immunohorizons|June 3, 2025
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalizationPhillip Scheinberg, Matt R Khoshnevis, Philip A Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|February 10, 2016
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.
Clinical Pharmacology and Therapeutics|December 16, 2017
Population Pharmacokinetics of Durvalumab in Cancer Patients and Association With Longitudinal Biomarkers of Disease StatusPaul G Baverel, Vincent F S Dubois, Chao Yu Jin, et al.
British Journal of Clinical Pharmacology|April 25, 2022
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjectsShringi Sharma, Xavier Pepin, Jean Cheung, et al.
Archives of Pathology & Laboratory Medicine|November 21, 2018
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial CarcinomaMagdalena Zajac, Anne-Marie Boothman, Yong Ben, et al.
Chemical Research in Toxicology|February 3, 2012
Cytochrome P450 11A1 bioactivation of a kinase inhibitor in rats: use of radioprofiling, modulation of metabolism, and adrenocortical cell lines to evaluate adrenal toxicityDonglu Zhang, Oliver Flint, Lifei Wang, et al.
Cancer Chemotherapy and Pharmacology|March 8, 2013
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignanciesLaura Q M Chow, Derek I Jonker, Grace K Dy, et al.
Clinical Lung Cancer|July 23, 2019
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer PatientsSriram Sridhar, Luis Paz-Ares, Hao Liu, et al.
Cancer Immunology Research|January 14, 2014
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitorMargaret K Callahan, Gregg Masters, Christine A Pratilas, et al.
Immunohorizons|June 3, 2025
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalizationPhillip Scheinberg, Matt R Khoshnevis, Philip A Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.
Pageof 11